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Objectives: Minimally invasive transoral robotic surgery (TORS) is less likely to necessitate 
gastrostomy tube (GT) following resection of head and neck lesions versus conventional open 
procedures. However, the incidence of and indications for GT after TORS has not been reported 
in detail. This study defines the incidence of intra- and postoperative gastrostomy following 
robotic resection of advanced head and neck disease. It seeks to clarify the relevance of GT after 
TORS. 
Design: Adult patients undergoing TORS and neck dissection (ND) from 2008-2014 were 
identified in the New York Statewide Planning and Research Cooperative System (SPARCS) all-
payer administrative database.  
Methods: Demographic data and timing of GT in relation to surgery were recorded. Emergency 
Department (ED) visits and inpatient readmissions were compared with multivariable logistic 
analysis. 
Results: Of the 441 included patients, immediate, delayed and total GT incidence within the first 
postoperative year was 9.5%, 11.6% and 21.1%, respectively. GT complications resulted in 4.5% 
of 30-day ED visits, 3.3% of 30-day readmissions, and 3.5% of 90-day readmissions. Thirty-nine 
percent of 90-day readmissions were linked to poor postoperative oral intake. Delayed GT status 
was associated with an increase in 30-day ED visits, and 30 or 90-day readmissions attributable 
to poor oral intake (p=0.10, p<0.0001, 0.002, respectively).  
Conclusions:  Even in the era of minimally invasive transoral robotic surgery, impaired oral 
intake is a significant postoperative burden to head and neck cancer patients with advanced 
disease. Attention to patient risk factors combined with a complicated hospital course may 
identify patients benefiting from early GT. 
Key word: gastrostomy, PEG, g-tube, TORS, cancer Level of Evidence: 2c 
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Gastrostomy in the Era of Minimally Invasive Head and Neck Cancer Surgery 
 
Introduction 
Gastrostomy tubes (GT) provide necessary alimentation for many patients with advanced 
head and neck cancer who require chemotherapy, radiation and/or surgical treatment. They avoid 
nutritional deficits in patients recovering from morbid operations and in those patients with 
impaired postoperative functional outcomes, such as dysphagia. However, GT can also 
negatively impact patient quality of life, and placement is not without risk or complications.
1
 The 
procedure should not be employed without calculation of the benefits versus the risks. 
Prior to the emergence of minimally invasive surgical techniques, gastrostomy was 
routine for at-risk patients undergoing head and neck cancer therapies. Open resection of 
difficult-to-reach head and neck neoplasms frequently requires GT. High-risk patients 
undergoing definitive chemoradiotherapy often receive prophylactic gastrostomy.
2, 3
 However, 
the development of transoral robotic surgery (TORS) by the University of Pennsylvania 
(Philadelphia, PA) in 2004 shifted this paradigm.
4
 Fewer TORS patients require gastrostomy 
than similar patients undergoing non-surgical therapy or open resection.
5, 6




There is a paucity of data regarding indications for gastrostomy in TORS, particularly in 
locally advanced Stage III or IV (M0) disease. TORS is FDA approved for resection of smaller 
(T1 and T2) malignancies, however it is becoming increasingly utilized for more advanced 
lesions (up to T4a oropharyngeal), which may lead to greater nutritional challenges in the 
perioperative period.
8-10
 Current reports on gastrostomy incidence in TORS have small numbers, 
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are often institution-based, and have a high proportion of early stage disease. The purpose of this 




Following Institutional Review Board approval, the New York Statewide Planning and Research 
Cooperative System (SPARCS) all-payer administrative database was used to identify all 
TORS.
7
 Patients were tracked with a unique patient identifier. ND and robotic procedures (ICD-
9 17.41-17.45, 17.49 or CPT S2900) were identified through ICD-9/CPT codes. Patients who 
were <18 years, had multiple resections (n=2) or had procedures staged with >6 month intervals 
(n=19) were excluded. Patient characteristics, including age, gender, race/ethnicity, region, 
facility type, payer, concurrent versus staged ND, surgical site, and comorbidities were 
identified. Inpatient complications, readmissions and Emergency Department (ED) visits were 
evaluated. Inpatient complications were defined as occurring during surgical admission, not 
readmission. Readmissions were evaluated 30 and 90 days following surgery. For patients with 
GT, only those placed during or after TORS + ND were considered (n=98). Patients receiving 
GT within the first postoperative year were further analyzed (n=93). Surgeon volume was 
considered. Low volume surgeons (LVS) performed an average of ≤5 TORS/year over nonzero 
years.
8
 High volume surgeons (HVS) performed >5 TORS/year. Diagnosis codes for readmission 
and ED visits were analyzed. GT complications were identified (ICD-9 536.4). Patient records 
demonstrating a GT complication without record of GT placement (n=3) were included for the 
purpose of calculating overall GT complication rates, but these patients were excluded from 
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further subgroup analyses. Frequency of diagnoses attributable to poor oral intake (ICD-9 276, 
536.2, 783, 787.0, 787.2) were compared between no GT, immediate and delayed GT groups. 
 
Statistical Methods 
A Chi-square test with exact P-values based on Monte Carlo simulation was used to compare 
categorical variables among patients having immediate GT, delayed GT and not having a GT. 
Logistic regression models were used to compare differences in readmission or ED visits. Any 
GT, as well as variables which were significant in the univariate analysis at the significance level 
of 0.1 were further included in the multivariable regression models while applying the forward 
selection process considering the number of events per variable issue.
11
 All analyses were 
performed using SAS 9.3 (SAS Institute Inc., Cary, NC), and statistical significance was set at 
0.05. SPARCS restricts reporting cell size <6. 
 
Results 
There were 441 patients who underwent TORS + ND from 2008 through 2014. In this 
group, 9.5% of patients underwent immediate GT (n=42) and 90.5% did not undergo immediate 
GT (n=399). Of those patients who did not receive an immediate GT, 12.8% required delayed 
GT placed within the first postoperative year (n=51). The average time to delayed GT was 
62±59 days. At one year, the total incidence of having had a GT placed was 21.1% (n=93). No 
significant differences existed between patients with and without GT in terms of age, gender, 
race, ND timing, or surgeon volume (Table 1). Medicare/Medicaid patients had slightly higher 
GT rates than commercially insured patients (p=0.06). The patient factors that were associated 
with need for and timing of GT included fluid and electrolyte disorder or weight loss (FED), 
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liver disease, alcohol abuse, paralysis and hypertension. Inpatient GT complications occurred in 
2.4% (n=1) of the immediate GT group. GT complications resulted in 4.5% (n=4) of 88 ED visits 
within 30 days, 3.3% (n=2) of 61 readmissions within 30 days, and 3.5% (n=4) of 114 
readmissions within 90 days. 
A minority of patients harbored the diagnosis of FED preoperatively (4.8%, n=21). Of the 
21 patients with preoperative FED, 61.9% (n=13) did not receive an immediate gastrostomy. 
However, patients with preoperative FED were more likely to receive a GT within one year of 
surgery (FED, 52.4% vs. no FED, 19.5%, p<0.001). At the time of postoperative discharge, 36 
patients carried a diagnoses of FED, but only 50% (n=18) had or subsequently received a GT. 
Immediate GT placement was most frequently associated with a complicated hospital 
course. All patients with an immediate GT (n=42) experienced at least one complication 
throughout their operative hospital course, compared to 70.6% of patients with a delayed GT 
(n=36) and 57.5% patients without GT (n=200, p<0.0001). However, the delayed GT group had 
the highest rates of ED visits and readmission within 30 days and 90 days when compared to 
immediate GT and no GT groups (p=0.03, <0.01, <0.0001, respectively) (Table 2). 
Thirty and 90-day readmissions and 30-day ED visits occurred overall in 12.2% (n=54), 
19.3% (n=85), and 14.1% (n=62) of patients. Reasons for ED visits and readmission were then 
reviewed, comparing immediate or delayed GT and no GT groups (Table 3). Twenty-seven 
percent of total ED visits (n=23) were linked to poor postoperative oral intake. Thirty-six percent 
of 30-day readmissions (n=22) and 38.6% of 90-day readmissions were linked to poor 
postoperative oral intake. Delayed GT status was associated with an increase in 30-day ED visits 
attributable to poor oral intake, however this was not statistically significant (p=0.10). Delayed 
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GT status was significantly associated with an increase in 30 and 90-day readmissions 
attributable to poor oral intake (p<0.0001, 0.002, respectively) (Figure 1). 
 
Discussion 
Our study is the first to consider the clinical impact of potential GT under-utilization in 
minimally invasive TORS patients with locally advanced head and neck cancer. We clearly 
identify a subpopulation of TORS patients treated for Stage III or IV disease who fail to thrive in 
the immediate postoperative period and ultimately require GT. We uniquely propose an 
aggressive early GT strategy aimed to minimize the delayed GT subset of the studied population. 
Their poor oral intake is a common cause of both readmission and return to the ED following 
TORS + ND. Postoperative readmission rates are increasingly used as proxy indicators of 
surgeon performance and hospital system quality. Targeting nutrition with or without GT in 
these patients could significantly improve surgeon operative outcomes and hospital 
reimbursement. 
 Other studies have considered post-TORS GT rates and potential predisposing factors.
12-
16
 GT rates are generally low for TORS. For early stage disease, few, if any, patients require 
GT.
17
 Not surprisingly, more complicated TORS patients may have higher GT rates. Iseli et. al. 
demonstrate T4 primary site disease is an independent predictor of GT after TORS.
18
 Al-Khudari 
et al. sites that salvage TORS or TORS plus free flap have 50% and 80% GT rates, 
respectively.
14
 However, Weinstein et al. showed that most Stage III or IV TORS + ND patients 
do not require long-term GT.
9
 Given the published data to date, our observation that 
approximately one-third of patients undergoing TORS for advanced disease may derive benefit 
from short-term perioperative improvements in nutrition – a benefit which appears unexpected 
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and ultimately resulted in GT – is of clear value. 
The delayed GT patients in this study utilize significantly greater health care resources 
postoperatively. Paradoxically, however, they have a less complicated initial hospital course than 
immediate GT patients. It is unexpected for patients with a more benign hospital course to 
experience increased rates of fluid and electrolyte disruption, weight loss, failure to thrive, 
dysphagia and inability to tolerate oral feeding. Future studies that are prospective, randomized, 
and that utilize clinical nutritional and functional outcomes data may better elucidate the nuances 
of why this discrepancy is observed in our study. Given that delayed GT patients represent a 
minority (11.5%) of the patients in this study, a refined, rather than an overarching, risk-
screening strategy should be used to identify patients benefiting from early GT in minimally 
invasive robotic resection of advanced head and neck cancers.  
Evidence-based guidelines to predict the need for gastrostomy exist, but high-quality 
evidence to support specific timing and screening criteria for tube feeds is lacking.
19
 It is 
generally accepted that demographics, tumor site and staging, nutritional status, and the presence 
of dysphagia play a role in risk stratification. Brown et al. describes a validated high-risk 
stratification protocol for head and neck cancer patients undergoing chemotherapy and radiation 
in which patients meet gastrostomy criteria if they exhibit >10% unintentional weight loss or 
BMI <20 with 5-10% weight loss in past 6 months, or they meet other criteria for severe 
malnutrition as judged by a dietician.
3
 The findings of this study suggest that perioperative fluid 
and electrolyte disorders, weight loss, liver disease, alcohol abuse, paralysis, hypertension and 
the presence of any perioperative complication contribute a high risk nutritional status following 
TORS, and these patient characteristics could be included in future rubrics.  
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The benefit of early GT with respect to head and neck surgery is controversial. 
Specifically, for TORS, 26.7% of surveyed surgeons routinely do not place either nasogastric or 
gastrostomy feeding access, and only 2.2% of surgeons routinely place a PEG.
7
 Chandler et al. 
outlines a preoperative scoring system to predict gastrostomy specific to head and neck 
reconstruction, with emphasis on low preoperative albumin as a major risk factor for 
postoperative complications.
20
 Mays et al. found that perioperative GT with respect to head and 
neck tumor resection suggests a high risk patient with a complicated hospital stay, but also that 
preoperative GT can protect against poor postoperative outcomes, such as prolonged hospital 
length of stay, wound complications, and weight loss.
21
 Our data also suggests that postoperative 
outcomes can be improved by aggressive nutritional screening and early GT in appropriate 
candidates undergoing robotic primary head and neck tumor resection. 
This study is subject to the inherent limitations of a retrospective observational study, 
particularly surgeon selection bias when deciding on GT timing. The data are dependent on an 
administrative database, and thus are not clinically rich with tumor staging, histology, 
intraoperative details or postoperative laboratory data. This data is specific to the SPARCS 
database, which only includes patients within New York State.  Data may not be extrapolated for 
the remainder of the United States, where trends may be different.  
 
Conclusion 
More than one-third of 30 and 90-day readmissions in TORS and neck dissection for 
advanced head and neck cancer in NY are related to impaired PO intake.  A disproportionate 
number of these readmissions occur in patients with delayed GT.  Patient risk factors combined 
with a complicated hospital course can identify patients benefiting from early GT, enhancing 
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postoperative resource utilization.  Future prospective studies are needed to evaluate the true 
benefit of early GT in appropriate head and neck cancer surgical candidates, and how improved 
risk-stratification for this intervention may effect postoperative outcomes. An improved 
understanding of the benefits of GT in this population can assist surgeons during informed 
consent, and help them to balancing quality of life decisions versus potentially avoidable hospital 
readmissions.   
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Table 1.    Characteristics and Comorbidities of Patients Undergoing Gastrostomy 
    Total, n No GT, n(%) Delayed GT n(%) Immediate GT n(%) P-value 
Age <55 138 116 (33.3) 11 (21.6) 11 (26.2) 
0.3   55-75 288 207 (59.5) 33 (64.7) 24 (57.1) 
  >75 39 25 (7.2) 7 (13.7) 7 (16.7) 
Gender Male 345 269 (77.3) 43 (84.3) 33 (78.6) 
0.54 
  Female 96 79 (22.7) 8 (15.7) 9 (21.4) 
Race Caucasian 338 266 (76.4) 42 (82.4) 30 (71.4) 
0.88 
  African American 29 23 (6.6) <6 <6 
  Spanish/ Hispanic 24 18 (5.2) <6 <6 
  Other 50 41 (11.8) <6 <6 
Insurer Medicaid 10 6 (1.7) <6 <6 
0.14 
  Medicare 126 92 (26.4) 19 (37.3) 15 (35.7) 
  Commercial 302 247 (71.0) 31 (60.8) 24 (57.1) 
  Other <6 <6 0 0 
Surgery Type Concurrent 349 281 (80.8) 37 (72.6) 31 (73.8) 
0.28 
  Staged 92 67 (19.2) 14 (27.4) 11 (26.2) 
Surgeon 
Volume Low 180 149 (42.8) 16 (31.4) 15 (35.7) 0.24 
  High 261 199 (57.2) 35 (68.6) 27 (64.3) 
FED Absent 405 330 (94.8) 45 (88.2) 30 (71.4) 
0.0001 
  Present 36 18 (5.2) 6 (11.8) 12 (28.6) 
Comorbidity Congestive heart 
failure 
7 <6 <6 <6 1.00 













51 39 (11.2) <6 7 (16.7) 0.50 
  Hypothyroidism 23 18 (5.2) <6 <6 0.50 
  Renal failure 16 10 (2.9) <6 <6 0.17 
  Liver disease 10 <6 <6 <6 <0.01 
  Obesity 43 34 (9.8) <6 <6 0.81 
  Paralysis <6 <6 <6 <6 0.03 
  Alcohol abuse 27 14 (4.0) <6 9 (21.4) <0.0001 
  Depression 27 22 (6.3) <6 <6 0.95 
  Hypertension 215 156 (44.8) 35 (68.6) 24 (57.1) <0.01 
P < 0.05 is highlighted. Data <6 suppressed due to small cell size publication restrictions.   FED = Fluid and electrolyte 
or weight loss disorder. 
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Table 2. GT Status and Postoperative Hospitalization 
  GT Status, n (%) 
P-Value 
  None Immediate Delayed 
Any 30-day ED 
visit 
41 (11.8) 9 (21.4) 12 (23.5) 0.03 
More than one 
ED visit 
12 (3.4) <6 7 (13.7) 0.05 
Any 30-day 
readmission 
34 (9.8) 6 (14.3) 14 (27.5) <0.01 
Any 90-day 
readmission 
51 (14.7) 9 (21.4) 25 (49.0) <0.0001 
More than one 
90-day 
readmission 
<6 <6 10 (19.6) <0.001 
GT = Gastrostomy tube. ED = Emergency department. P<0.05 
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Table 3. Reasons for Postoperative Hospitalization 
Visit Type GT Status 
Hospital Visits P-Value 
Total, 




50* 10 (20.0) 
0.10 Immediate 
GT 13 4 (30.8) 
Delayed GT 20 9 (45.0) 
30-Day, Readmission 
No GT 36 6 (16.7) 
<0.0001 
Immediate 
GT 7 2 (28.6) 
Delayed GT 18 14 (77.8) 
90-Day, Readmission 
No GT 55* 14 (25.0) 
0.002 
Immediate 
GT 15 5 (33.3) 
Delayed GT 42 25 (59.5) 
GT = Gastrostomy Tube. P<0.05 is highlighted. *Three patient records (five ED visits and two 90-day 
readmission) were excluded. Values <6 suppressed due to cell size restrictions. 
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Figure 1. Paradoxical increase in postoperative readmissions despite fewer perioperative 
complications in patient with delayed GT versus early GT. Delayed GT patients have increased 




ND = Neck dissection 
SOAR = Surgical Outcomes Analysis Research 
SPARCS = Statewide Planning and Research Cooperative 
TORS = Transoral Robotic Surgery 
GT = Gastrostomy tube 
ED = Emergency department 
LVS = Low volume surgeons  
HVS = High volume surgeons 
FED = Fluid, electrolyte, weight loss disorder 
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